Special Issue

Topic: Sickle Cell Disease(SCD): Progress in Research and Insights

A Special Issue of Rare Disease and Orphan Drugs Journal

ISSN 2771-2893 (Online)

Submission deadline: 31 Aug 2024

Guest Editor(s)

Dr. Marina Cavazzana
Director of the Department of Biotherapy at Necker Hospital, Paris Descartes University; Paediatric Immunology, Hôpital Necker Enfants Malades, Paris, France.
Dr. Thiago Trovati MacIel
Laboratory of Cellular and Molecular Mechanisms of Haematological Disorders and Therapeutical Implications, Imagine Institute, Paris, France.

Special Issue Introduction

Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders resulting from a mutation in the beta-globin gene (Glu6Val). This genetic mutation leads to the production of abnormal hemoglobin (hemoglobin S or HbS), causing red blood cells to become rigid and sickle-shaped. With a substantial global prevalence, SCD impacts millions of people worldwide, particularly in sub-Saharan Africa, the Middle East, and India. The disease is associated with high morbidity and mortality rates, with patients often suffering from severe pain episodes termed vaso-occlusive crises. Over the years, the FDA has approved several pharmacological treatments for SCD, including hydroxyurea, L-glutamine, and voxelotor. These treatments have shown efficacy in managing the disease and its co-morbid conditions, such as acute chest syndrome and stroke, thereby improving the quality of life for many patients.

Despite these advancements, the search for novel treatments continues. The recent approval of gene therapy for SCD has opened a new chapter in the treatment of this disease. This innovative curative approach involves modifying a patient’s own stem cells to produce normal or anti-sickling hemoglobin, thereby mitigating the severity of the disease. While gene therapy holds great promise, some patients may not be eligible for this treatment, especially in areas with limited access to specialized care. Therefore, medical research remains crucial in this field. The insights gained from ongoing research will not only enhance our understanding of SCD but also pave the way for the development of more effective and accessible treatments. The progress made in SCD research underscores the importance of sustained investment in this area, with the ultimate goal of improving patient outcomes and quality of life.

Submission Deadline

31 Aug 2024

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/rdodj/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=rdodj&IssueId=rdodj240204
Submission Deadline: 31 Aug 2024
Contacts: Stella Wang, Assistant Editor, assistant_editor@rdodjournal.com

Published Articles

Coming soon
Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us


All published articles are preserved here permanently:



All published articles are preserved here permanently: